What are the typical clinical features of ivermectin toxicity at low, moderate, and high doses?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Ivermectin at standard therapeutic doses (≈150–200 µg/kg) is generally well tolerated but can cause mild gastrointestinal and transient systemic effects; toxicity becomes progressively neurological and, at high or veterinary-level exposures, life‑threatening with coma and seizures [1] [2] [3]. Animal experiments and human case reports converge on liver enzyme changes and central nervous system (CNS) depression as dose‑related signals, but the human overdose literature is limited and complicated by formulation differences and coinfections [4] [5] [6].
1. Low-dose / therapeutic exposure — mild, mostly transient adverse effects
At recommended human doses used to treat onchocerciasis or other parasitic infections (about 150–200 µg/kg), most adverse events are mild and transient: nausea, diarrhea, abdominal discomfort and occasional headache or dizziness have been reported in clinical use and safety reviews of ivermectin [1] [7]. Controlled human pharmacology studies testing larger repeated dosing regimens up to single doses of 90–120 mg recorded focused safety monitoring but did not show a consistent pattern of severe toxicity in healthy volunteers, although ocular complaints (blurred or altered color vision) and CNS effects were specifically assessed [8]. Systematic reviews conclude serious neurological adverse events at standard doses are uncommon in the absence of co‑factors such as Loa loa infection [6].
2. Moderate overdose — increasing gastrointestinal and neurologic complaints
When doses exceed therapeutic ranges—whether accidental ingestion of veterinary preparations or intentional supratherapeutic self‑medication—patients commonly present with worsening GI symptoms plus early neurologic signs: lethargy, restlessness, confusion, visual disturbances and ataxia have been documented in case reports and clinical summaries of human overdoses [5] [2]. Poison‑control guidance advises hospital evaluation for exposures above roughly 2 mg/kg because at these intermediate multiples of therapeutic dose there is a risk of CNS penetration and progressive symptoms [2]. Meta‑analyses of higher human dosing regimens note that CNS adverse events rise with exposure (Cmax/AUC), though variability in pharmacokinetics can mask clear dose–response relationships in trials [6].
3. High-dose / severe toxicity — CNS depression, seizures, coma; hepatic and ocular signals
At high exposures—commonly seen with veterinary formulations or massive overdoses—clinical toxicity shifts to frank neurologic compromise: profound CNS depression, mydriasis, loss of pupillary reflexes, limb hypotonia, fasciculations, seizures and coma are described in veterinary series and human case narratives alike [3] [9] [5]. Animal LD50 data place acute toxic ranges in the single‑digit to tens of mg/kg (rats 5–50 mg/kg or ~51.5 mg/kg depending on method), indicating a wide margin between human therapeutic microgram/kg dosing and lethal animal doses, but species and route differences limit direct translation [10]. Repeated‑dose animal studies also flag the liver as a toxic target at medium–high regimens: increased liver coefficients, elevated ALT and LDH and histopathologic changes were reported in a 14‑day rat intraperitoneal study [4] [11]. Human high‑dose trials monitored for QTc, mydriasis and CNS adverse events precisely because ocular and hepatic signals have appeared in pooled reports [8] [12].
4. Mechanisms, vulnerable populations and confounders that shape the clinical picture
Ivermectin’s antiparasitic action involves chloride‑channel modulation (glutamate‑gated and GABA receptors); toxicity at high systemic levels likely reflects CNS GABAergic and related inhibition when the blood‑brain barrier is breached or P‑glycoprotein function is impaired—this explains breed‑specific sensitivity in dogs (e.g., collies) and the role of drug interactions or genetic differences in humans [13] [6]. Coinfections such as Loa loa can amplify neurologic risk; veterinary formulations often contain solvents not present in human products and can produce additional toxicity, confounding human case reports from veterinary exposures [3] [2].
5. Evidence limits and practical implications for clinicians and public health
Human evidence on clear dose thresholds for specific syndromes is sparse: randomized trials of higher doses report tolerability data but are underpowered to detect rare serious neurological events, and case reports are heterogeneous in product, dose and co‑exposures [8] [6] [5]. Clinically, moderate to severe presentations mandate supportive care and hospital observation (poison control recommends evaluation for >2 mg/kg exposures), with attention to neurologic status, liver enzymes and ocular findings given signals from animal studies and volunteer monitoring [2] [4] [8]. Where assertions exceed these sources—such as precise human toxic thresholds for seizure risk—reporting is limited and further controlled pharmacokinetic–clinical correlation is needed [6].